Persistent depressive disorder

Last reviewed: 24 Apr 2022
Last updated: 19 Apr 2022

Summary

Definition

History and exam

Key diagnostic factors

  • chronic mood disorder lasting greater than 2 years
  • depressive symptoms present for most of the day, most days
  • no periods of euthymia in the past 2 years (1 year for children or adolescents)
  • symptoms of major depression may be continuously present for 2 or more years
More key diagnostic factors

Other diagnostic factors

  • no symptoms of mania/hypomania or schizophrenia
  • absence of underlying medical conditions, medication use, or substance abuse that could cause the mood disorder
  • fatigue or low energy
  • low self-esteem
  • poor concentration
  • feelings of hopelessness
  • weight changes
  • sleep disturbance
Other diagnostic factors

Risk factors

  • positive family history
  • female sex
More risk factors

Diagnostic investigations

1st investigations to order

  • medical evaluation
  • CBC
  • thyroid function tests
  • metabolic panel
  • vitmain D
  • Patient Health Questionnaire (PHQ-9)
  • Beck Depression Inventory (BDI)
  • Quick Inventory of Depressive Symptoms (QIDS)
More 1st investigations to order

Investigations to consider

  • vitamin B12
  • urine test
  • ECG
More investigations to consider

Treatment algorithm

ACUTE

all patients

Contributors

Authors

David J. Hellerstein, MD
David J. Hellerstein

Professor of Clinical Psychiatry

Columbia University Medical Center

Director, Depression Evaluation Service

New York State Psychiatric Institute

New York

NY

Disclosures

DJH has received grant support from Eli Lilly, Pfizer, Forest Pharmaceuticals, GlaxoSmithKline, and Bristol-Myers Squibb, GeneSight, Marinus, Takeda, Intracellular Therapies, and Compass Pathways. He is an author of a number of references cited in this topic.

Acknowledgements

Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic. DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.

Peer reviewers

Dean F MacKinnon, MD

Associate Professor

John Hopkins University

Baltimore

MD

Disclosures

DK declares that he has no competing interests.

James H Kocsis, MD

Professor

Weill Cornell Medicine

New York

NY

Disclosures

JK has professionally collaborated with the authors.

Neil Nixon, BSc, MMedSci, MBBS, FRCPsych

Associate Professor in Psychiatry

Institute of Mental Health

University of Nottingham

Nottingham

UK

Disclosures

NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.

  • Differentials

    • Major depressive disorder
    • Bipolar disorders (bipolar I, bipolar II, bipolar disorder not otherwise specified)
    • Cyclothymic disorder
    More Differentials
  • Guidelines

    • Depression in children and young people: identification and management
    • Clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments
    More Guidelines
  • Patient leaflets

    Depression in adults: what is it?

    Depression in adults: what treatments work?

    More Patient leaflets
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer